



CBD

CORTICOBASAL DEGENERATION

A report on our current knowledge, research and initiatives
towards finding a cure.



CBD SOLUTIONS



Contact

Karin & Sten Mörtstedt CBD Solutions AB
Center for Molecular Medicine L8:01
Karolinska Universitetssjukhuset
SE-171 76 Stockholm, Sweden

www.cbdsolutions.se
info@cbdsolutions.se

January 2018

Contents

About CBD Solutions	4
About the Founder – Sten Mörtstedt.....	5
The Research is Essential – Our Daily Operations.....	6
About Corticobasal Degeneration	7
About Tau.....	7
Diagnostics and Treatment	8
The Research to Date	9
Building a Network.....	9
Tau and the Stages of CBD	10
Foretelling and Diagnosing CBD.....	11
Looking Toward the Future.....	13
Research Network	14
Patient Experience	15
Patient Information	15
Collaborators and Funded Projects.....	16
Board of Directors	18
Advisory Board.....	19
Closing Words from the CEO.....	19



GLOSSARY

Basal ganglia – strongly interconnected with the cerebral cortex, thalamus and brainstem. Associated with functions including: control of voluntary motor movements and cognition.

Cohort – a group of patients with similar symptoms.

Dysphasia – a partial or complete impairment of the ability to communicate resulting from brain injury.

GWAS – genome-wide association study: A study to see if any gene variant is associated with a trait.

Parkinsonism – a group of neurological disorders with symptoms like tremors and muscular rigidity.

PET – Positron Emission Tomography, an imaging technique.

Prion diseases – a disease which is caused by prions. Prions are structurally altered versions of small proteins that are normally expressed in cells.



About CBD Solutions

- Research to Solve the Mystery Behind Corticobasal Degeneration

CBD Solutions was founded in 2013 with the goal to find a cure for the disease Corticobasal Degeneration (CBD). Our vision is to bring together the best researchers in the field, to fund and support their work to find a treatment and generate more awareness about this disease.

CBD is a terminal, rare and devastating neurodegenerative disease. The lack of research and diagnostic methods has made finding a cure a challenging task. However, we at CBD Solutions are determined to provide the best conditions for scientists and medical professionals to work together to solve the mystery. We believe that increased collaboration between all those involved in this field could make it possible to develop a diagnostic approach in the near future, and ultimately find a cure for those who are suffering.

The way that CBD Solutions work is unique in the research world. It is fully funded by the founder Sten Mörststedt's charitable trust, this allows CBD to focus all its efforts on working in collaboration with world leading scientists and researchers, with patient groups,

charities and the pharmaceutical industry. The goal is to act as a catalyst to those entities and facilitate cooperation between them. The scientists and clinicians that we partner with are conducting research at world-renowned universities across the globe. By partnering with them we hope to enable more discussions and collaborations.

We aim to gather all available data in one place (www.cbdsolutions.se) for those who want to learn more about the disease or pursue research in this field. A greater understanding for this disease is needed in order to provide earlier diagnosis, improve the quality of life for those who are affected, and make sure patients get the right treatment.

About the Founder

Sten Mörtstedt

Sten Mörtstedt is a businessman and philanthropist. He has first-hand experience of seeing how the neurodegenerative disease Corticobasal Degeneration (CBD) affects the patient and the patient's family. When his wife Karin was diagnosed with CBD, they discovered a general lack of awareness about the disease and how to

treat those affected. Through witnessing the devastating effects of the disease, and discovering the lack of support, funding and research, Mr. Mörtstedt became determined to make a change. Consequently he launched CBD Solutions which is fully funded by the Sten and Karin Mörtstedt Family & Charity Trust.

“My vision is to bring attention to the disease, team up with the best researchers around the world, and to take on the challenge to find a cure for CBD. We want to help the patients and their families. By actively partnering with the best scientists in this field, we hope to encourage them to explore this area of medicine, and we believe that together we can bring innovative solutions to those suffering from CBD. Not only do we want to be a platform for the research community, but we also want to gather information where patients and their families, and anyone interested can find knowledge. We hope that more people become aware of CBD, and we encourage more patients to join the passionate research teams in their studies.”



The Research is Essential – Our Daily Operations

When we started in 2013, we saw a lack of research and attention in the field, but we could also see the potential to solve the mystery of the disease. Since then, we have seen the researchers we partner with work hard and passionately to find a solution to the disease. CBD Solutions is currently supporting several research projects, world-renowned scientists and clinicians from all over the globe. Their research covers a broad range of areas focused on both diagnostics and finding a treatment for Corticobasal Degeneration (CBD). Some of the scientists we partner with are developing a patient cohort and a worldwide network to connect researchers and to share knowledge. Through this network, we see how important it is for this small community of researchers to exchange experiences. This increase both public awareness and professional knowledge about the condition. While it provides support for patients, it is also a vital way to build a solid infrastructure in this relatively new field. It is very satisfying to see how the network has developed to become an important resource for researchers and patients.

Other researchers are focusing on improving diagnostic methods by understanding the underlying mechanisms behind CBD, so that patients can receive treatment early on. There are three overarching areas of research that CBD Solutions is currently focusing on:

- Identifying the underlying mechanisms for the disease
- Finding diagnostic methods
- Finding a therapeutic solution

CBD Solutions collaborates daily with:

- KI (Karolinska Institutet)
- UCL (University College London)
- UPenn (University of Pennsylvania)
- Mayo Clinic
- UCSF (University of California, San Francisco)
- C2N Diagnostic
- NSgene
- Cortice Bioscience

About Corticobasal Degeneration

Corticobasal Degeneration (CBD) is a rare and progressive neurodegenerative disease that is believed to be related to an abnormal accumulation of tau protein in the brain. The exact prevalence of CBD is still unknown, but researchers estimate that it affects approximately 1-5 in every 100 000 people.

Most patients are around the age of 60. The true prevalence could be higher since many patients are misdiagnosed with diseases that are similar to CBD. The cause of CBD is still unknown, and currently, there are no treatments available and it is difficult for patients to receive a correct diagnosis while alive. The only way to confirm a CBD diagnosis is post mortem.

Some of the initial symptoms shown include physical complications such as: stiffness, shakiness, jerkiness, slowness and clumsiness in the extremities. The symptoms usually begin on one side of the body and gradually spread to the other. They also worsen over time, as the disease progresses. Further symptoms may include:

- Dysphasia (difficulties with speech generation)
- Dysarthria (difficulties with articulation)
- Apraxia (inability to perform or repeat particular movements)
- Aphasia (disconnected speech patterns)
- Alien limb syndrome (failure of the patient to control movement resulting in a sensation that a limb is "alien" or "foreign")
- Myoclonus (jerky, rapid movements, difficulties controlling the muscles of the face and mouth, walking or balancing difficulties)
- Parkinsonism (rigidity, slow movements, postural instability)
- Tremors
- Mild-to-moderate cognitive impairment (memory loss, difficulty planning or executing unrehearsed movements, dementia)

Although the symptoms of CBD overlap with other neurodegenerative diseases, such as Parkinson's disease and Progressive Supranuclear Palsy (PSP), it is believed that CBD and Alzheimer share the same construction. So a solution, or cure, to CBD could be highly correlated with one to Alzheimer's disease.



ABOUT TAU

The tau protein is present in all nerve cells and is important for the cell structure and its ability to divide and transport substances. If this protein becomes structurally altered it will form twisted fibers inside the cells that will eventually destroy them. This mechanism is the cause of various neurological diseases. It is believed that toxic tau that accumulates in the areas of the brain called cortex and basal ganglia can cause CBD. Initially the nerve cells will only be swollen and damaged but as the disease progresses the cells will be destroyed, and the patient will gradually become worse.



Diagnosics and Treatment

Diagnosics

One of the biggest challenges with Corticobasal Degeneration (CBD) today is the inability to give a definite diagnosis while a patient is still alive. CBD belongs to a group of rare neurodegenerative diseases that correspond to four main overlapping syndromes. These syndromes are known by the collective neuropathological term Frontotemporal Lobar Degeneration (FTLD) and include: CBD, Frontotemporal Dementia (FTD), Primary Progressive Aphasia (PPA), and Progressive Supranuclear Palsy Syndrome (PSPS).

Because of its rarity and nonspecific clinical characteristics, CBD is often assumed to be Parkinsons or even Alzheimers disease. A misdiagnosis most unfortunate for patients.

A clinical diagnosis of CBD is based on certain criteria that are correlated with the disease. A diagnosis is often given by eliminating other neurodegenerative diseases first. However, since the symptoms can vary from patient to patient, and some only occur rarely, it is difficult to diagnose based on elimination alone. A clinical diagnosis typically involves a neurological examination, using electrophysiological studies that identify

changes in brain function over time; CT or MRI scans, as well as laboratory evaluations.


Today, a postmortem diagnosis is the only existing tool that gives a definitive answer to the presence of CBD. In these cases, the brain is examined by a pathologist, who makes a diagnosis of CBD that is characterized by the unnatural accumulation of tau protein.

Treatment

Since the exact cause of CBD still is unknown and there are no treatments currently available that inhibit or slow down the progress of CBD, we see a real need for new research in both diagnosics and treatments.

The existing treatments for patients focus on alleviating their symptoms. Currently, for example, some believe that the most effective way to treat the symptoms of parkinsonism is with dopaminergic drugs. Unfortunately, this results in only moderate and short-term relief for the patient.

Regular physiotherapy and speech therapy are two non-pharmacological treatments that can help many patients ease their symptoms and improve the quality in their daily life.



The Research To Date

The majority of the pioneering research and advances on CBD have occurred within the last decade due to the relatively recent formal recognition of the disease. With more widespread awareness of CBD, an increasing number of departments and faculties have become active contributors to the field. So now, the interest in CBD research is increasing each year. However, since the disease is so rare, a main priority is to locate and gather larger patient groups for clinical studies.

Building a Network

One project, focused on creating a worldwide network, is led by Dr. Huw Morris, Professor of Clinical Neuroscience at UCL Institute of Neurology (ION). His aim is to develop and maintain a CBD register consisting of a pan-European network of patients who can be available for future therapeutic, biomarker, genetic and clinic-pathological studies. Dr. Morris' team has also set up a network of clinicians across more than 40 study sites. Through the network, the team hopes to share knowledge and connect patients and clinicians globally. In addition, the team is collecting crucial data, performing memory tests and detailed MRI brain scans to more accurately distinguish the disease and ultimately improve the diagnostic methods.

“We are trying to understand the genetic mechanisms behind CBD, and we want to connect clinicians and



Dr. Huw Morris

Honorary Consultant Neurologist at the Royal Free Hospital and the National Hospital for Neurology and Neurosurgery (NHNN).

“It is crucial that we get more data in order to continue this important research.”

teams who want to help. With the network, we can not only connect the clinicians; we can also connect patients who wish to be involved in clinical trials. There are many things we can do to see this development go faster. By setting up the network, we hope that we can identify risk factors, and find patterns, which will ultimately help us find a diagnosis earlier.”

Tau and the Stages of CBD

Two areas where we have seen great scientific advances in recent years are the study of genetics and abnormal protein accumulation and their impact on the progression of neurodegenerative diseases. Progress has also been made in potential diagnostics and treatment methods.

Earlier research found that the rapidly progressive neurodegenerative disorder Creutzfeldt Jakob disease was caused by an abnormal and “toxic” folding pattern in a newly discovered brain protein. This misfolded protein, which is a characteristic of prion diseases, induces nearby normal proteins creating a chain reaction that spreads throughout the brain. Evidence from the past five years suggests that a similar mechanism, operating more slowly and affecting different proteins, is at work in other neurodegenerative diseases including CBD. We know that the normal tau protein is present in all neurons, and plays an important role in their structure and function. Scientists have already determined that affected CBD brain cells contain deposits of abnormal forms of tau protein. In patients with CBD, tau in their brains is abnormally phosphorylated, which stops it from functioning properly.



Dr. Helen Ling

MRCP, PhD
Senior Research Associate and Neurologist

“The goal is to find the mechanisms that influence the start and spread of the disease.”

Dr Helen Ling is a neurologist and senior post-doctoral research associate from the Institute of Neurology at the University College London. Dr Ling has a main research interest in neurodegenerative conditions related to abnormal tau accumulation. Through CBD Solutions, she is currently investigating the pathological staging of CBD and its related clinical symptoms by applying various techniques using post-mortem brain tissue to understand the pattern of tau distribution and how it spreads as the disease progresses, while correlating these findings with clinical features. Dr Ling has looked after and followed some of these patients who chose to donate their brains for research to help further the cause. By identifying patterns on why, how and where the tau protein spreads, she hopes to understand what triggers the initial neurodegeneration process and how tau spreads as the disease progresses.

“The goal is to find the mechanism behind the disease. We want to understand where it starts, how it

spreads, and where it spreads. These findings will help us identify therapeutic strategies to cure the disease. Ultimately, we want to be able to diagnose patients at the early stage of their illness. We have seen many great developments throughout the years, but we need to continue the research to make further advances. So, it is of utmost importance that we continue to work together with patients in order to gather enough data.”

The work of Dr. Ling has now been extended and the researchers have already identified additional CBD-associated genes that were not found in earlier analyses. Like previously known, it seems that defects in how the brain cells handle various proteins may be central to the development of CBD and the other neurodegenerative diseases. Examples of such defects in protein handling include overproduction, inappropriate folding and deficiencies in the disposal of worn, defective or excess proteins.



Dr. Per Svenningsson

Professor of Neurology,
Karolinska Institutet


“Collaborations between researchers is key.”

Professor Per Svenningsson, a neurologist who is also heading an experimental laboratory at the Karolinska Institute in Stockholm, has done research into basal ganglia for more than 20 years. In his practice he follows patients with CBD and has become very concerned about the lack of proper diagnostics and therapies for this devastating disorder. Support from CBD Solutions has enabled him to develop diagnostic and prognostic biomarkers that can be used as objective measures in future clinical therapy trials.

He has also initiated studies on models to understand how and where tau pathology affects different parts of the brain. In the coming years, he will investigate the effects of potential therapies in these models and hopefully also on some of the patients suffering from CBD. In his studies, he collaborates with several other researchers, who are also supported by CBD Solutions, to ensure that his research brings truly novel results that will ultimately benefit patients.

Foretelling and Diagnosing CBD


Today, many new and exciting clinical trials are under way, several of them funded by CBD Solutions. At the Karolinska Institute (KI) in Sweden, two studies are



looking to improve diagnosis, by improving the identification and categorization of the specific biomarkers related to CBD. Researchers hope this will improve diagnostic accuracy and possibility for disease progression to be quantified. There is also a study intended to develop new and better models that test the disease and drug mechanisms, as well as possible drug's effectiveness. At the University of California (UCSF) similar goals are within reach where new scales are being developed to measure the progression of the disease and the impact of new therapies in the future.

Another study is being conducted in cooperation among University College London (UCL), the University of Pennsylvania and the Mayo Clinic, and is looking into the influence that certain genes have on the development of CBD. Through GWAS sequencing of DNA (for which a CBD diagnosis has been confirmed by pathological examination), the researchers hope to identify new genes that may increase the risk of CBD. Meanwhile researchers at UCL are hoping to better

understand the disease by mapping how it spreads in the brain and identifying new disease mechanisms. If researchers can connect the dots between high-risk genes and their effects, we will develop a much better understanding of CBD's impact on the human brain. UCL is also focusing research on certain skin cells (fibroblast) from patients with tauopathies to develop cellular models that better replicate the disease and its progression. At The Karolinska Institute in Sweden, clinical trials around PET tau imaging is being evaluated. The goal is to find the ligands that specifically bind to the tau protein. The hope is that by using Positron Emission Tomography (PET) to visualise where pathological tau aggregates in the living brain of CBD patients, a more focused treatment can be developed. This is also the hope of Dr. Adam Boxer, a neurologist at the University of California in San Francisco's Memory and Aging Centre. Dr. Boxer is one of the researchers funded by CBD Solutions and specialises in Alzheimer's disease,



frontotemporal dementia and atypical Parkinsonism (CBD and PSP). He directs the Neurosciences Clinical Research Unit at the Sandler Neurosciences Centre at Mission Bay, as well as the Alzheimer's disease and Frontotemporal Dementia Clinical Trials Program at the Memory and Aging Centre.



“One of the major difficulties is to identify and diagnose patients in time.”

Dr. Adam Boxer

Professor of Neurology,
University of California, San Francisco

For the past fifteen years Dr. Boxer has focused his research on trying to solve the mystery of CBD. He points out that one of the major difficulties for researchers today is identifying the patients in time and to distinguish them from patients who are diagnosed with Alzheimer's or Parkinson's disease. That is why Dr. Boxer's lab is currently conducting research on how to develop precise eye tracking methods to gauge mental fitness and to identify cognitive decline decades before the first symptoms appear. This promising diagnostic treatment is being investigated using quantitative eye movement and neuroimaging (MRI and PET) to measure and study the pathophysiology of cognitive and motor impairments in CBD and other progressive neurodegenerative diseases.

He has previously designed and led the first US based, multi-center, randomized, placebo-controlled, clinical trial of a therapeutic agent for the treatment of PSP. Now researchers are working on the development of tau antibodies with therapeutic potential for CBD and PSP. The hypothesis is that these antibodies will bind the so called “toxic” tau and block the disease spreading in the brain. To draw on this, other CBD solutions funded researchers are looking at a new technology that uses encapsulated cells biodelivery with the hope that the technology, if developed, can facilitate antibody delivery into the brain. Several clinical trials are also being conducted by UCSF and Cortice Biosciences on the safety of the new drug to treat CBD and other tauopathies. TPI 287 is a microtubule-stabilizing drug that might be helpful in treating CBD. Together, these discoveries could contribute immensely to move CBD treatment research forward.

The Needs in Research

Even though research is in the early stages, the future looks bright. A dream scenario is that an effective treatment could be deployed within ten years. There is a good chance that new treatments and drugs will have a greater positive impact in treated patients, but they need to be tested. The first step is to slow the progression of the disease. Future studies are needed to replicate present findings and to complete comparisons with other patient groups, such as those with PSP and Parkinson's Disease – these comparisons will be particularly important, since they share many similar symptoms and underlying mechanism. Although it is an uncommon form of dementia, CBD is also providing an example of the future possibilities of using functional imaging in the clinical evaluation of dementia related illnesses.

Mechanism of Tau


The most promising lead currently is the discovery of the integral part that the tau protein plays in CBD. As mentioned, tau is present in all the neurons in the brain, and it plays an important role in the structure and function of neurons. In CBD, tau is abnormally phosphorylated, and this biochemical change keeps it from functioning properly. This form of “toxic” tau spreads from neuron to neuron and if we can stop the spread, we can also halt the disease. In the best-case scenario, it might be possible to halt the progress of the disease by genetically designed antibodies that bind to the tau protein.

Diagnostics

To summarize, patients need to be diagnosed at a much earlier stage than they are today. Due to the similarities with other diseases, many CBD patients can be misdiagnosed for years and in many cases the diagnosis can only be obtained after death. Using Positron Emission Tomography (PET) to visualise pathological tau aggregates in the living brain of CBD patients, together with research on precise eye tracking methods that identify cognitive decline decades before the first symptoms appear, could speed up diagnosis.

Treatment

New drugs that target tau are already entering human clinical trials; however, assessing their effectiveness have not been established yet. The data generated from these kinds of research project will hopefully allow researchers to design better clinical trials and so help make this assessment possible. There is another emerging approach to disease treatment and prevention that looks at the individual variability in genes, environment, and lifestyle of each person. This approach, also called personalized



medicine, will allow doctors and researchers to predict and more accurately tailor treatments and prevention strategies for particular groups of patients. This contrasts with a “one-size-fits-all” approach, where the disease treatment and prevention strategies are developed for the average person, with less consideration for the differences between individuals. This is something CBD researchers have learned from their colleagues in cancer research, where precision medicine has become very successful.

Research network and Patient samples

Because the disease is so rare it is hard to find patients for clinical trials. This lack of patient data may deter pharmaceutical companies from pursuing research in this field. To attract more scientists and corporations we need to create a research infrastructure with controlled

clinical trials and the tools to measure success. The overall reaction from the medical community is positive and helpful. We also see how the medical community collaborates to share knowledge, yet we need to continue to encourage great clinicians and corporations to pursue this field of research. The short-term ambition is to partner with different entities to secure new drugs and therapies that target the tau protein. The long-term ambition is to develop a large stable international research network to test drugs and therapies on large patient samples. This is something that cancer research has been doing for a long time with good results. The hope is that it will be possible for CBD patients to receive the latest drugs and therapies. This in turn will help researchers by providing them with much needed additional data.

A Patient Experience



"The physiotherapy really helps me maintain a better level of physical activity."

Mrs. Harriet König

Mrs. Harriet König is a CBD patient based in Sweden. Mrs. König was, like many other patients, first diagnosed with Parkinson's disease. Ever since her diagnosis three years ago, she has remained hopeful that she will be able to continue with her hobbies, despite the drastic changes the diagnosis and the symptoms have had in her daily life. A former art teacher by profession, she continues to paint despite the difficulties her symptoms have given her. The painting also helps her keep the

movement in her hands. In a conversation with CBD Solutions Mrs. König mentions her physiotherapy as one form of treatment.

"I get help with physiotherapy on a weekly basis, where I train my hand movements. The physiotherapy really helps me maintain a better level of physical activity", says Mrs. König. "We all need more information about CBD and its mechanisms. The disease needs to become more well known amongst physicians and researchers so that patients can receive a diagnosis faster and treatment accordingly. My hopes for the future are that more people will see the benefits of research in the area and that young researchers want to enter this field of research and that physicians can learn more about the disease. Scientists and pharmaceutical companies must pursue the research, and find a cure for CBD", she concludes.



PATIENT INFORMATION

There are several organisations devoted to improving awareness, education, care and finding a cure for neurodegenerative diseases. The organisations CurePSP as well as the PSP Association are there to answer CBD related questions and provide support for patients and caregivers. There are also several national organisations such as the National Health Service (NHS) in the United Kingdom and Parkinsonförbundet in Sweden. You can also find more information, including experiences from other patients, in the CBD section of the patient forum PatientsLikeMe.com.

Many CBD patients and caregivers want to emphasise the importance of physical exercise to promote longevity, decrease the risk of falls, and enable more stable functioning. The positive effects of physical exercise are supported by published data, although research also tells us that CBD patients still need to be cautious about the risk of falling. We therefore recommend that patients make contact with a physiotherapist to set up a training program to suit their particular needs.


CBD Solutions also sponsor the development of a CBD patient registry in Europe. The purpose of this registry is to support clinical research in CBD and to facilitate future clinical trials. If you are interested in participating or would like further information please contact Dr Ruth Lamb at University College London (ruth.lamb@ucl.ac.uk).

You can find more information at: www.psp.org, www.pspassociation.org.uk, www.nhs.uk/conditions/Corticobasal-degeneration/, www.parkinsonforbundet.se

Projects Funded by CBD Solutions

We support several projects led by world renowned scientists and dedicated biotechs to achieve our goal to cure CBD. Our collaborators are spread all over the world:

- 1 UCSF, San Francisco, USA
 - 2 Mayo Clinic, Jacksonville, USA
 - 3 C2N Diagnostics, Saint Louis, USA
 - 4 curePSP, Baltimore, USA
 - 5 The Feinstein Institute for Medical Research, New York, USA
Cortice Bioscience, New York, USA
 - 6 NSgene, Providence, USA
-
- 7 University College London (UCL), London, UK
 - 8 Alzecure Foundation, Stockholm, Sweden
Karolinska Institute (KI), Stockholm, Sweden
-
- 9 National Institute of Radiological Science (NIRS), Chiba, Japan
-
- Tau Consortium, Worldwide



Research projects funded by CBD solutions:

Stem Cell Models (iPSc) - UCL

Skin cells (fibroblast), from patients with tauopathies, is used to develop (induced pluripotent stem cells) cellular models that better replicate the disease.

Genetics – UCL, UPenn, Mayo Clinic

Through GWAS and exome sequencing of pathological confirmed CBD patients DNA, we identify new genes that may increase risk for CBD.

Pathology - UCL

By studying brains - donated by CBD patients, we map spreading and identify new disease mechanisms.

Animal Models - KI


New and better animal models are developed to test disease mechanism and drugs.

Biomarkers - KI

Identification of biomarkers will improve diagnosis accuracy and enable quantification of disease progression.

CBD patient cohorts - UCL

CBD patient cohorts is being constructed to facilitate future clinical studies and clinical trials of potential therapies.



Brain delivery – NSgene

A new technology, using encapsulated cells biodelivery, is developed to facilitate antibody delivery into the brain.

Scales – UCSF

New scales are being developed to facilitate quantification of disease progression and effects of future therapies.

Tau antibodies – C2N Diagnostic

Development of Tau antibodies with therapeutic potential in CBD. The hypothesis is that these antibodies will bind toxic tau and block disease spreading in the brain.

PET tau imaging – NIRS, KI

Using positron emission tomography (PET) to visualize pathological tau aggregates in the living brain of CBD patients.

Clinical trials – UCSF, Cortice Bioscience

Safety study of TPI-287 to treat CBD and PSP.

Board of Directors



Sten Mörtstedt (Chairman)

Sten Mörtstedt, a businessman and philanthropist, has a consistent track record spanning a period of over 40 years, of building profitable and sustainable businesses. He is the founder and Executive Director of CLS Holdings plc, a pan-European property company that he established in 1987 and took to a listing on the main market of the London Stock Exchange in 1994. In addition to his focus on property, he has been commercially active in a number of investment areas outside the property arena and has seen a number of the companies in which he has invested through to successful stock exchange listings or trade sales.



Ingvar Dahlqvist (member)

Ingvar Dahlqvist has a BA in economy. He has worked for several years in Europe for a French industrial group as the Business Controller and Financial Director for market development and also as Managing Director. Today he is a member or the chairman on the boards of a number of Swedish and French companies. He is also the chairman of the Parkinson Association in the south of Sweden and sits on the election committee of the National Parkinson Association of Sweden.



Björn Bloth (Vice Chairman)

Björn Bloth, MD, PhD, Associated Professor, works as a scientific and medical advisor to several foundations and organisations. He has a PhD in Medical microbiology and immunology and a board certification in Internal Medicine.



Anna Seeley (member)

Anna Seeley (née Mörtstedt) is a qualified Chartered Surveyor and has worked in the property industry for over 20 years. She has held various positions within the property departments of General Electric, BT Group and CLS Holdings. She holds a degree in property valuation and finance from City University. Anna is also on the board of directors of the Sten and Karin Mörtstedt Family and Charity Trust.



Angela Crawley (member)

Angela Crawley has a BA in Psychology and a MA in Psychotherapy. She has a private practice in the London area.

CBD Solutions Advisory Board

Professor Anthony E. Lang
Movement Disorders Centre
[Toronto Western Hospital](#)

Professor Irene Litvan
Tasch Endowed Professor in
Parkinson's Disease Research
Director of the Movement Disorder Centre
[University of California, San Diego](#)

Professor Thomas Perlmann
[Karolinska Institutet Stockholm](#)

Professor Michael A. Schwarzschild
[Harvard Medical School, Boston](#)

Professor Per Svenningsson
[Karolinska Institutet Stockholm](#)

Professor Håkan Widner
[Lund University Hospital](#)

Professor Stefan Lorenzl
[Ludwig Maximilian University of Munich](#)



"I joined CBD Solutions because of its unique and personal approach of partnering with scientists," says Professor Samuel Svensson, CEO of CBD Solutions.

"Our ultimate goal is to solve the mystery of CBD – understand why some people are affected and understand how it can be treated. It is important that we continue with the strides that we have made so far. While we continue to support and partner with the best researchers in this field worldwide, we also want to encourage others to contribute. Whether you are a medical practitioner, a researcher, a patient, a family member, or just curious about the topic, we hope that you will join us with your expertise and passion in order to continue our work together and spread the word about CBD. I am convinced that together we can solve the mystery of CBD and bring patients the treatment that they are waiting for."

– Samuel Svensson, CEO, CBD Solutions



CBD SOLUTIONS